Completed treatment as planned per-protocol, reinforcing the strength of its proprietary drug candidate, CMND-100. The study achieved its primary endpoint of safety and tolerability. CMND-100 demonstrated a consistent safety profile throughout the dose-escalation phase, including at the highest dose evaluated in the fourth cohort. No serious adverse events were observed, and overall tolerability remained strong and consistent with earlier cohorts, further supporting the compound’s continued clinical advancement.

Clearmind noted that Part A of the study employed a sequential single-ascending- dose of approximately 20 mg, 40 mg, 80 mg, and 160 mg of CMND-100 in healthy volunteers (six participants per cohort). Successfully advancing through all planned dose levels while maintaining a favorable safety profile marks a meaningful milestone for a non-hallucinogenic neuroplastogen-derived therapeutic. Unlike classical psychedelic approaches, which often encounter practical and regulatory limitations due to perceptual effects; CMND‑100’s  safety and tolerability findings, including at the highest dose tested, - support its continued development as a potentially accessible treatment option. These results further support the program’s differentiated clinical profile and reduce key early‑stage development risks as the asset progresses toward subsequent phases.